SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Martín Dib; Nicole Le Corre; Catalina Ortiz; Daniel García; Marcela Ferrés; Constanza Martinez-Valdebenito; Cinthya Ruiz-Tagle; María José Ojeda; Manuel A. Espinoza; Aquiles Jara; Juan Pablo Arab; Ricardo Rabagliati; Cecilia Vizcaya; María Elena Ceballos; Mauricio Sarmiento; Sebastián Mondaca; Macarena Viñuela; Antonia Pastore; Vania Szwarcfiter; Elizabeth Galdames; Aldo Barrera; Pablo Castro; Nicolás MS Gálvez; Jorge A. Soto; Susan M. Bueno; Alexis M. Kalergis; Bruno Nervi; M. Elvira Balcells

doi:10.1016/j.lana.2022.100371

SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Martín Dib, Nicole Le Corre, Catalina Ortiz, Daniel García, Marcela Ferrés, Constanza Martinez-Valdebenito, Cinthya Ruiz-Tagle, María José Ojeda, Manuel A. Espinoza, Aquiles Jara, Juan Pablo Arab, Ricardo Rabagliati, Cecilia Vizcaya, María Elena Ceballos, Mauricio Sarmiento, Sebastián Mondaca, Macarena Viñuela, Antonia Pastore, Vania Szwarcfiter, Elizabeth GaldamesAldo Barrera, Pablo Castro, Nicolás MS Gálvez, Jorge A. Soto, Susan M. Bueno, Alexis M. Kalergis, Bruno Nervi, M. Elvira Balcells

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

18 Citas (Scopus)

Resumen

Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. Funding: School of Medicine, UC-Chile and ANID. ClinicalTrials.gov

Idioma original	Inglés
Número de artículo	100371
Publicación	Lancet Regional Health - Americas
Volumen	16
DOI	https://doi.org/10.1016/j.lana.2022.100371
Estado	Publicada - dic. 2022
Publicado de forma externa	Sí

Áreas temáticas de ASJC Scopus

Políticas sanitarias
Medicina interna
Salud pública, medioambiental y laboral

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.lana.2022.100371

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Dib, M., Le Corre, N., Ortiz, C., García, D., Ferrés, M., Martinez-Valdebenito, C., Ruiz-Tagle, C., Ojeda, M. J., Espinoza, M. A., Jara, A., Arab, J. P., Rabagliati, R., Vizcaya, C., Ceballos, M. E., Sarmiento, M., Mondaca, S., Viñuela, M., Pastore, A., Szwarcfiter, V., ... Balcells, M. E. (2022). SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study. Lancet Regional Health - Americas, 16, Artículo 100371. https://doi.org/10.1016/j.lana.2022.100371

@article{a9258ebb308b4a3aa5b976aee60253c7,

title = "SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study",

abstract = "Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. Funding: School of Medicine, UC-Chile and ANID. ClinicalTrials.gov",

keywords = "BNT162b2, CoronaVac, COVID-19, SARS-CoV-2, Solid organ transplant, Vaccine, Vaccine immunogenicity",

author = "Mart{\'i}n Dib and {Le Corre}, Nicole and Catalina Ortiz and Daniel Garc{\'i}a and Marcela Ferr{\'e}s and Constanza Martinez-Valdebenito and Cinthya Ruiz-Tagle and Ojeda, {Mar{\'i}a Jos{\'e}} and Espinoza, {Manuel A.} and Aquiles Jara and Arab, {Juan Pablo} and Ricardo Rabagliati and Cecilia Vizcaya and Ceballos, {Mar{\'i}a Elena} and Mauricio Sarmiento and Sebasti{\'a}n Mondaca and Macarena Vi{\~n}uela and Antonia Pastore and Vania Szwarcfiter and Elizabeth Galdames and Aldo Barrera and Pablo Castro and G{\'a}lvez, {Nicol{\'a}s MS} and Soto, {Jorge A.} and Bueno, {Susan M.} and Kalergis, {Alexis M.} and Bruno Nervi and Balcells, {M. Elvira}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = dec,

doi = "10.1016/j.lana.2022.100371",

language = "English",

volume = "16",

journal = "Lancet Regional Health - Americas",

issn = "2667-193X",

publisher = "Elsevier Ltd",

}

Dib, M, Le Corre, N, Ortiz, C, García, D, Ferrés, M, Martinez-Valdebenito, C, Ruiz-Tagle, C, Ojeda, MJ, Espinoza, MA, Jara, A, Arab, JP, Rabagliati, R, Vizcaya, C, Ceballos, ME, Sarmiento, M, Mondaca, S, Viñuela, M, Pastore, A, Szwarcfiter, V, Galdames, E, Barrera, A, Castro, P, Gálvez, NMS, Soto, JA, Bueno, SM, Kalergis, AM, Nervi, B & Balcells, ME 2022, 'SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study', Lancet Regional Health - Americas, vol. 16, 100371. https://doi.org/10.1016/j.lana.2022.100371

TY - JOUR

T1 - SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines

T2 - A prospective cohort study

AU - Dib, Martín

AU - Le Corre, Nicole

AU - Ortiz, Catalina

AU - García, Daniel

AU - Ferrés, Marcela

AU - Martinez-Valdebenito, Constanza

AU - Ruiz-Tagle, Cinthya

AU - Ojeda, María José

AU - Espinoza, Manuel A.

AU - Jara, Aquiles

AU - Arab, Juan Pablo

AU - Rabagliati, Ricardo

AU - Vizcaya, Cecilia

AU - Ceballos, María Elena

AU - Sarmiento, Mauricio

AU - Mondaca, Sebastián

AU - Viñuela, Macarena

AU - Pastore, Antonia

AU - Szwarcfiter, Vania

AU - Galdames, Elizabeth

AU - Barrera, Aldo

AU - Castro, Pablo

AU - Gálvez, Nicolás MS

AU - Soto, Jorge A.

AU - Bueno, Susan M.

AU - Kalergis, Alexis M.

AU - Nervi, Bruno

AU - Balcells, M. Elvira

PY - 2022/12

Y1 - 2022/12

N2 - Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. Funding: School of Medicine, UC-Chile and ANID. ClinicalTrials.gov

AB - Background: Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster. Funding: School of Medicine, UC-Chile and ANID. ClinicalTrials.gov

KW - BNT162b2

KW - CoronaVac

KW - COVID-19

KW - SARS-CoV-2

KW - Solid organ transplant

KW - Vaccine

KW - Vaccine immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=85138592528&partnerID=8YFLogxK

U2 - 10.1016/j.lana.2022.100371

DO - 10.1016/j.lana.2022.100371

M3 - Article

AN - SCOPUS:85138592528

SN - 2667-193X

VL - 16

JO - Lancet Regional Health - Americas

JF - Lancet Regional Health - Americas

M1 - 100371

ER -

SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study

Resumen

Áreas temáticas de ASJC Scopus

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto